How Genetically Modified T-Cells Fight CD19 Cancers

This patent describes how to create and use genetically modified human T cells that target and kill cancer cells expressing the CD19 protein, offering a new way to treat blood cancers.

What it covers

This patent describes a specialized human cell, often a T cell, that has been genetically engineered to fight cancer. The cell contains a 'lentiviral vector' carrying instructions for a 'chimeric antigen receptor' (CAR). This CAR is designed with a 'CD19 antigen binding domain' (specifically, the amino acid sequence of SEQ ID NO: 20) to recognize a protein called CD19 found on certain cancer cells. It also includes a 'transmembrane domain' to anchor it, a 'costimulatory signaling region' with 4-1BB to boost the T cell's activity, and a 'CD3 zeta signaling domain' to trigger the cell to kill the cancer. For example, a patient with leukemia could have their own T cells modified with this CAR and then re-infused to target and destroy their CD19-expressing cancer cells.

What it doesn't cover

• —Does not cover CAR T-cells that target other cancer-specific proteins besides CD19.
• —Does not cover CAR T-cells that use different costimulatory signaling regions than 4-1BB.
• —Does not cover CARs that lack a CD3 zeta signaling domain.
• —Does not cover gene delivery methods other than lentiviral vectors.
• —Does not cover treating solid tumors, as the claims focus on CD19-expressing cells and hematological cancers.
• —Does not cover cells that are not derived from a human having cancer for treatment purposes.

The clever bit

The novelty lies in the specific combination of genetic elements within the CAR, particularly the CD19 binding domain (SEQ ID NO: 20) paired with the 4-1BB costimulatory signaling region and the CD3 zeta signaling domain. This precise arrangement allows the modified T cells to not only recognize and bind to cancer cells but also to become fully activated and sustained in their attack.

Why it matters

This patent is foundational to the field of CAR T-cell therapy, a revolutionary approach to treating certain cancers. It specifically details the design of a CAR targeting CD19, a key marker on many blood cancers like leukemia and lymphoma. This technology has led to the development of highly effective treatments for patients who have exhausted other options, transforming the outlook for some hematological malignancies.

Real-world examples

• 1.Kymriah (tisagenlecleucel) for B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma
• 2.Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma
• 3.Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma
• 4.Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma
• 5.Abecma (idecabtagene vicleucel) for multiple myeloma